Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study
- PMID: 18684196
- PMCID: PMC2574666
- DOI: 10.1111/j.1572-0241.2008.02034.x
Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study
Abstract
Objective: Case series suggest that nonalcoholic fatty liver disease (NAFLD) is associated with increased all-cause and cardiovascular mortality. The current study compared the survival of subjects with and without suspected NAFLD in a population-based cohort, and placed the finding in the context of previously published case series.
Methods: Primary analysis assessed mortality for NHANES-III participants with and without suspected NAFLD using the National Death Index. Suspected NAFLD was based upon unexplained ALT elevation. The Olmsted County and Cleveland Clinic case series were also used for comparison. Survivals were compared using Proportional Hazards Model and direct age standardization.
Results: The NHANES cohort included 980 with and 6,594 subjects without suspected NAFLD. Over a mean of 8.7 yr, suspected NAFLD had a hazards ratio of 1.37 (95% CI 0.98-1.91) for all-cause mortality. In the 45-54 age group, suspected NAFLD had significantly higher all-cause (4.40 95% CI 1.27-13.23) and cardiovascular mortality (8.15, 95% CI 2.00-33.20) after adjusting for conventional cardiovascular risk factors. The age-standardized rate per 10,000 per year was 129 (95% CI 118-140) for the NHANES non-NAFLD cohort, 154 (95% CI 116-198) for the NHANES suspected NAFLD cohort, 214 (95% CI 157-279) for the Olmsted County series, and 426 (95% CI 298-573) for the Cleveland Clinic series.
Conclusion: The magnitude of mortality risk in NAFLD depends on the setting and method of ascertainment. Suspected NAFLD in the 45-54 age group is a strong independent risk factor for cardiovascular death and warrants further cardiovascular risk management guidelines.
Conflict of interest statement
Figures
Comment in
-
NAFLD and cardiovascular risk: direct evidence for the tale of two ages.Am J Gastroenterol. 2009 Jul;104(7):1851-2. doi: 10.1038/ajg.2009.233. Am J Gastroenterol. 2009. PMID: 19574981 No abstract available.
Similar articles
-
Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study.Am J Gastroenterol. 2010 Jul;105(7):1567-73. doi: 10.1038/ajg.2010.18. Epub 2010 Feb 9. Am J Gastroenterol. 2010. PMID: 20145609 Free PMC article.
-
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.J Hepatol. 2008 Oct;49(4):608-12. doi: 10.1016/j.jhep.2008.06.018. Epub 2008 Jul 9. J Hepatol. 2008. PMID: 18682312
-
In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.Metabolism. 2013 Mar;62(3):352-60. doi: 10.1016/j.metabol.2012.08.005. Epub 2012 Sep 19. Metabolism. 2013. PMID: 22999011
-
Selenium intake in relation to all-cause and cardiovascular mortality in individuals with nonalcoholic fatty liver disease: A nationwide study in nutrition.PLoS One. 2024 May 20;19(5):e0303140. doi: 10.1371/journal.pone.0303140. eCollection 2024. PLoS One. 2024. PMID: 38768120 Free PMC article.
-
Fatty liver, cardiometabolic disease and mortality.Curr Opin Lipidol. 2020 Feb;31(1):27-31. doi: 10.1097/MOL.0000000000000652. Curr Opin Lipidol. 2020. PMID: 31789677 Review.
Cited by
-
Cardiorespiratory fitness, waist circumference, and alanine aminotransferase in youth.Med Sci Sports Exerc. 2013 Apr;45(4):722-7. doi: 10.1249/MSS.0b013e31827aa875. Med Sci Sports Exerc. 2013. PMID: 23190589 Free PMC article.
-
Association between Cardiorespiratory Fitness, Relative Grip Strength with Non-Alcoholic Fatty Liver Disease.Med Sci Monit. 2020 Jun 19;26:e923015. doi: 10.12659/MSM.923015. Med Sci Monit. 2020. PMID: 32555123 Free PMC article.
-
NAFLD in 2014: Genetics, diagnostics and therapeutic advances in NAFLD.Nat Rev Gastroenterol Hepatol. 2015 Feb;12(2):65-6. doi: 10.1038/nrgastro.2014.232. Epub 2015 Jan 6. Nat Rev Gastroenterol Hepatol. 2015. PMID: 25560844 Free PMC article. Review.
-
Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.BMC Pediatr. 2013 May 23;13:85. doi: 10.1186/1471-2431-13-85. BMC Pediatr. 2013. PMID: 23702094 Free PMC article. Clinical Trial.
-
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.Dig Dis Sci. 2016 Dec;61(12):3425-3435. doi: 10.1007/s10620-016-4330-z. Epub 2016 Oct 6. Dig Dis Sci. 2016. PMID: 27714510 Review.
References
-
- Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387–95. - PubMed
-
- Ryan CK, Johnson LA, Germin BI, et al. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 2002;8:1114–22. - PubMed
-
- Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Vital Health Stat. 1994. National Center for Health Statistics. - PubMed
-
- Plan and operation of the Third National Health and Nutrition Examination Survey, 1988–94. Series 1: programs and collection procedures. Vital Health Stat 1. 1994:1–407. - PubMed
-
- Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137:1–10. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources